Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen
Autore:
Kayser, J; Ettinger, B; Pressman, A;
Indirizzi:
Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA Kaiser Permanente Med Care Program Oakland CA USA 94611 and, CA 94611 USA
Titolo Testata:
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
fascicolo: 5, volume: 8, anno: 2001,
pagine: 328 - 332
SICI:
1072-3714(200109/10)8:5<328:PHSDOR>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
REPLACEMENT THERAPY; WOMEN; CONTINUATION; MENOPAUSE; ATTITUDES; TRIAL; RISK;
Keywords:
menopause; estrogen replacement therapy; raloxifene; SERMs; continuation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
13
Recensione:
Indirizzi per estratti:
Indirizzo: Ettinger, B Kaiser Permanente Med Care Program, Div Res, 3505 Broadway, Oakland, CA 94611 USA Kaiser Permanente Med Care Program 3505 Broadway Oakland CA USA 94611
Citazione:
J. Kayser et al., "Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen", MENOPAUSE, 8(5), 2001, pp. 328-332

Abstract

Objective: To determine possible differences in continuation among women initiating treatment with the selective estrogen receptor modulator raloxifene, versus those initiating treatment with estrogen-containing regimens. Design: A pharmacy prescription database search for refill patterns. The study subjects were members of Kaiser Foundation Health Plan, a large healthmaintenance organization; 1,394 women age greater than or equal to 60 years who filled index prescriptions for either raloxifene (n = 331) or systemic estrogens (n = 1,063) between April 1998 and March 1999. The main outcomemeasure was discontinuation based on prescription refill patterns through December 2000. Results: At 24 months, the probabilities of discontinuing were 56% for women starting raloxifene compared to 72% for women starting estrogens. The likelihood of discontinuation was significantly less among women starting raloxifene than among those starting estrogen (hazard ratio = 0.75; 95% confidence interval = 0.64-0.88). Adjustments for age and prescriber specialty did not affect the risk. Conclusions: We conclude that discontinuation of estrogen by women well beyond the age of menopause is high; more than two-thirds discontinue within 2 years of starting. Women starting therapy with raloxifene are 25% percentless likely to discontinue their medication than those starting estrogen, providing some promise that long-term benefits of raloxifene may be more easily achieved than those of estrogen.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 09:16:19